Improved aerobic capacity in a randomized controlled trial of noncombustible nicotine and tobacco products.

What Was Tested

The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.

The trial offers a unique opportunity to prospectively examine the relationship between smoking behavior and aerobic capacity, and to examine-for the first time-the specific impact of exclusive EC or HTP use on V̇O2max.

Why It Was Studied

Specifically, no research has yet evaluated V̇O2max changes following a switch to electronic cigarettes (ECs) or heated tobacco products (HTPs).

This is a secondary analysis of the CEASEFIRE trial, a 12-weeks randomized controlled switching trial comparing the impact of ECs or HTPs on changes in smoking behaviour.

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized.

The participants were allocated by chance, so the Therapeutic nicotine (patch, non-peptide) group and the comparison group should start out alike.

What Was Measured

Specifically, no research has yet evaluated V̇O2max changes following a switch to electronic cigarettes (ECs) or heated tobacco products (HTPs).

This is a secondary analysis of the CEASEFIRE trial, a 12-weeks randomized controlled switching trial comparing the impact of ECs or HTPs on changes in smoking behaviour.

The subject headings attached to it are Smoking Cessation, Nicotine, Oxygen Consumption, Tobacco Products, Electronic Nicotine Delivery Systems, Cardiorespiratory Fitness and Exercise.

The authors tagged it with the keywords Aerobic capacity, Heated tobacco products, V̇O2max and e-cigarettes.

What This Means in Plain Language

The paper is a randomized study of Therapeutic nicotine (patch, non-peptide).

The publication is from 2025 (Scientific reports), a journal based in England.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.